Aardvark Therapeutics Inc (AARD)

Apr 27, 2025

Aardvark Therapeutics Inc’s Market Journey: Closing Strong at 7.79, Up 6.86 - DWinneX

Apr 27, 2025

Apr 23, 2025

Aardvark Therapeutics (NASDAQ:AARD) Trading Up 7.6% – What’s Next? - Defense World

Apr 23, 2025

Apr 16, 2025

Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 16, 2025

Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 09, 2025

Apr 07, 2025

Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com

Apr 07, 2025

Apr 02, 2025

Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World

Apr 02, 2025

Apr 01, 2025

Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

RBC Capital maintains $21 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times

Apr 01, 2025

Mar 31, 2025

Aardvark Therapeutics Inc. (AARD) reports earnings - qz.com

Mar 31, 2025

Mar 29, 2025

Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00 - Defense World

Mar 29, 2025

Mar 28, 2025

BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 27, 2025

Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks

Mar 27, 2025

Mar 27, 2025

BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com Australia

Mar 27, 2025

Mar 27, 2025

Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks

Mar 27, 2025

Mar 21, 2025

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha

Mar 21, 2025

Mar 18, 2025

Aardvark Therapeutics, Inc.’s Quiet Period Will End on March 25th (NASDAQ:AARD) - Defense World

Mar 18, 2025

Mar 14, 2025

Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Insider Monkey

Mar 14, 2025

Mar 12, 2025

Top 10 Insider Purchases Last Month - Insider Monkey

Mar 12, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World

Mar 11, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World

Mar 11, 2025

Mar 11, 2025

BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia

Mar 11, 2025

Mar 11, 2025

Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World

Mar 11, 2025

Mar 10, 2025

BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com

Mar 10, 2025

Mar 10, 2025

This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga

Mar 10, 2025

Mar 10, 2025

RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks

Mar 10, 2025

Mar 10, 2025

Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India

Mar 10, 2025

Mar 10, 2025

RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier - Marketscreener.com

Mar 10, 2025

Mar 10, 2025

Morgan Stanley sets Aardvark stock target at $29, rating Overweight By Investing.com - Investing.com South Africa

Mar 10, 2025

Mar 10, 2025

Morgan Stanley sets Aardvark stock target at $29, rating Overweight - Investing.com

Mar 10, 2025

Mar 04, 2025

San Diego had its first biotech IPO of 2025. Are more on the way? - MSN

Mar 04, 2025

Mar 03, 2025

Aardvark Therapeutics’ $94.2 Million Initial Public Offering - Global Legal Chronicle

Mar 03, 2025

Mar 03, 2025

Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey

Mar 03, 2025

Feb 24, 2025

IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip

Feb 24, 2025

Feb 23, 2025

Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.

Feb 23, 2025

Feb 21, 2025

Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.

Feb 21, 2025

Feb 20, 2025

Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics - TipRanks

Feb 20, 2025

Feb 20, 2025

Autism Spectrum Disorder Treatment Market Size is expected - openPR

Feb 20, 2025

Feb 20, 2025

Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com India

Feb 20, 2025